Abbott Toxicology Tdip Card Clia Waived

Yes, the Abbott Toxicology Tdip Card is specifically designed for rapid, qualitative drug screening. Its single-dip device format emphasizes speed and convenience for point-of-care (POC) testing.

Key features supporting rapid decentralized testing include:

• CLIA Waived Status: This classification enables its use in Physician Office Laboratories (POLs) and other decentralized settings that require less stringent laboratory certification.
• Single Dip Device Format: The design allows for quick specimen introduction and immediate visual results interpretation.
• Versatile Panel Configurations: The card is available in options ranging from a single-analyte test (OXY100) up to a comprehensive 10-Panel drug screen, allowing you to customize testing to specific needs.

Yes, the CLIA Waived status is a top selling point for the Abbott Toxicology Tdip Card, significantly simplifying the drug screening process.

This designation means the product meets the Clinical Laboratory Improvement Amendments (CLIA) requirements for low-complexity testing, offering several key advantages for facilities:

• Simplified Regulatory Burden: It complies with waived testing requirements, easing the regulatory burden compared to higher-complexity tests.
• Point-of-Care Suitability: It is ideal for use in decentralized settings like physician offices and occupational health clinics.
• Ease of Use: The single-dip device format is straightforward, designed to minimize the need for specialized laboratory equipment or highly trained personnel for administration and result interpretation.

The Abbott Toxicology Tdip Cards are CLIA Waived rapid screening devices, allowing for easy, presumptive drug testing in various clinical environments. All configurations are sold in boxes containing 25 tests.

The following single-dip device configurations are offered:

• 1-Panel Test: Screens for Oxymorphone (OXY100).
• 5-Panel Test (Variant 1): Screens for Amphetamine (AMP1000), Cocaine (COC300), Opiates (OPI2000), Phencyclidine (PCP25), and Tetrahydrocannabinol (THC50).
• 5-Panel Test (Variant 2): Screens for Amphetamine (AMP1000), Cocaine (COC300), Methamphetamine (MET1000), Opiates (OPI2000), and Tetrahydrocannabinol (THC50).
• 10-Panel Test: Provides comprehensive screening for Amphetamine (AMP1000), Barbiturates (BAR300), Benzodiazepines (BZO300), Buprenorphine (BUP10), Cocaine (COC300), Methamphetamine (MET1000), Methadone (MTD300), Opiates (OPI2000), Oxymorphone (OXY100), and Tetrahydrocannabinol (THC50).

All configurations of the Abbott Toxicology Tdip Cards are packaged with 25 individual tests per box (25/bx).

Yes, the Abbott Toxicology Tdip Card is specifically designed for rapid, convenient drug screening in point-of-care (POC) environments.

Its effectiveness for quick screening workflows stems from several key features:

• CLIA Waived Status: The device is classified as CLIA Waived, meaning it meets the standards for simple, low-complexity testing. This allows it to be used outside of traditional high-complexity laboratories in settings like clinical offices or occupational health facilities.
• Rapid Immunoassay: It functions as a rapid screening immunoassay for the qualitative detection of specific drugs and their metabolites in human urine, ensuring immediate results.
• Single-Dip Format: The test utilizes a simple, single-dip device mechanism, which streamlines the testing procedure and aids in rapid interpretation.

The Abbott Toxicology Tdip Card is manufactured in the United States.

Yes, the Abbott Toxicology Tdip Cards are ideal for point-of-care (POC) testing environments.

Their suitability is primarily due to their CLIA Waived Status (Clinical Laboratory Improvement Amendments). This designation certifies them as simple, low-complexity tests, making them appropriate for use in clinics, workplaces, or other non-laboratory settings that comply with CLIA standards for waived testing.

Features supporting rapid, on-site screening include:

• Rapid Testing Format: They utilize a simple single-dip device for quick, qualitative screening of drugs of abuse.
• Configurable Options: Versatile configurations are available, ranging from 1-panel to comprehensive 10-panel kits, allowing facilities to tailor screening based on specific needs.

Yes, the Abbott Toxicology Tdip Card is designed specifically for rapid drug screening in point-of-care (POC) settings.

Key features that make it ideal for these environments include:

• CLIA Waived Status: This designation allows its use in facilities meeting Clinical Laboratory Improvement Amendments waived testing requirements, simplifying regulatory compliance for physician offices or occupational settings.
• Single-Dip Format: It uses a user-friendly, single-dip device methodology for qualitative detection of drugs and metabolites in human urine.
• Versatile Configurations: The cards offer flexibility with options ranging from a single-test device (like OXY100) up to a comprehensive 10-panel screening device, accommodating diverse testing needs.

Yes, the Factory New condition ensures these Abbott Toxicology Tdip Cards are unused and in optimal state, which is essential for obtaining accurate diagnostic results.

This condition guarantees:

• Reliable Performance: The devices are consistent with factory specifications and suitable for diagnostic screening.
• Optimal Integrity: Because they are factory new and ship directly from the manufacturer, you receive inventory with maximum integrity, crucial for CLIA Waived testing environments.

The Abbott Toxicology Tdip Card is specifically intended for drug screening purposes. It uses a rapid, qualitative immunoassay to detect drugs in urine.